[{"id":"c89ce7a9-5aab-402c-b4e1-9d4c28a049b1","acronym":"TTX-080-001","url":"https://clinicaltrials.gov/study/NCT04485013","created_at":"2025-02-25T16:32:10.967Z","updated_at":"2025-02-25T16:32:10.967Z","phase":"Phase 1","brief_title":"TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers","source_id_and_acronym":"NCT04485013 - TTX-080-001","lead_sponsor":"Tizona Therapeutics, Inc","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • TTX-080"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 07/14/2020","start_date":" 07/14/2020","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-07"}]